The latest in a series of deals that Boehringer Ingelheim has inked in the oncology space will see the German family-run firm acquire US biotech Abexxa.

Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains. 

Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.

Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?